The inflammatory profile of exacerbations in patients with severe refractory eosinophilic asthma receiving mepolizumab (the MEX study): a prospective observational study.

[1]  P. Nair,et al.  Asthma exacerbations on benralizumab are largely non‐eosinophilic , 2020, Allergy.

[2]  I. Pavord,et al.  Response to mepolizumab treatment is sustained across 4-weekly dosing periods , 2020, ERJ Open Research.

[3]  Xin-chun Yang,et al.  Eosinopenia is associated with greater severity in patients with coronavirus disease 2019 , 2020, Allergy.

[4]  Z. Wang,et al.  Eosinopenia and elevated C-reactive protein facilitate triage of COVID-19 patients in fever clinic: A retrospective case-control study , 2020, EClinicalMedicine.

[5]  M. Rothenberg,et al.  Eosinophil responses during COVID-19 infections and coronavirus vaccination , 2020, Journal of Allergy and Clinical Immunology.

[6]  G. Canonica,et al.  The evolving algorithm of biological selection in severe asthma , 2020, Allergy.

[7]  L. Heaney,et al.  Different endotypes and phenotypes drive the heterogeneity in severe asthma , 2020, Allergy.

[8]  S. Yancey,et al.  Characterisation of Exacerbations of Severe Eosinophilic Asthma on Mepolizumab Compared to Placebo , 2019, B21. SEVERE ASTHMA: CLINICAL AND MECHANISTIC STUDIES.

[9]  I. Pavord,et al.  Remotely Monitored Therapy and Nitric Oxide Suppression Identifies Nonadherence in Severe Asthma , 2019, American journal of respiratory and critical care medicine.

[10]  I. Pavord,et al.  Exacerbations of severe asthma in patients treated with mepolizumab , 2018, European Respiratory Journal.

[11]  I. Pavord,et al.  Biological exacerbation clusters demonstrate asthma and chronic obstructive pulmonary disease overlap with distinct mediator and microbiome profiles , 2018, Journal of Allergy and Clinical Immunology.

[12]  James J. Lee,et al.  Sputum autoantibodies in patients with severe eosinophilic asthma , 2017, The Journal of allergy and clinical immunology.

[13]  C. Jenkins,et al.  Effect of azithromycin on asthma exacerbations and quality of life in adults with persistent uncontrolled asthma (AMAZES): a randomised, double-blind, placebo-controlled trial , 2017, The Lancet.

[14]  F. Albers,et al.  Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial. , 2017, The Lancet. Respiratory medicine.

[15]  H. Ortega,et al.  Role of local eosinophilopoietic processes in the development of airway eosinophilia in prednisone‐dependent severe asthma , 2016, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[16]  K. Ravin,et al.  The Eosinophil in Infection , 2016, Clinical Reviews in Allergy & Immunology.

[17]  Mike Thomas,et al.  Blood eosinophil count and prospective annual asthma disease burden: a UK cohort study. , 2015, The Lancet. Respiratory medicine.

[18]  I. Pavord,et al.  Airway bacteria measured by quantitative polymerase chain reaction and culture in patients with stable COPD: relationship with neutrophilic airway inflammation, exacerbation frequency, and lung function , 2015, International journal of chronic obstructive pulmonary disease.

[19]  D. Khatry,et al.  High blood eosinophil count is a risk factor for future asthma exacerbations in adult persistent asthma. , 2014, The journal of allergy and clinical immunology. In practice.

[20]  Ian D Pavord,et al.  Mepolizumab treatment in patients with severe eosinophilic asthma. , 2014, The New England journal of medicine.

[21]  James J. Lee,et al.  The consequences of not having eosinophils , 2013, Allergy.

[22]  E. R. Sutherland,et al.  A large subgroup of mild-to-moderate asthma is persistently noneosinophilic. , 2012, American journal of respiratory and critical care medicine.

[23]  Ian D Pavord,et al.  Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial , 2012, The Lancet.

[24]  S. Stanojevic,et al.  Multi-ethnic reference values for spirometry for the 3–95-yr age range: the global lung function 2012 equations , 2012, European Respiratory Journal.

[25]  Christopher E Brightling,et al.  Acute exacerbations of chronic obstructive pulmonary disease: identification of biologic clusters and their biomarkers. , 2011, American journal of respiratory and critical care medicine.

[26]  L. Spencer,et al.  Eosinophils in innate immunity: an evolving story , 2010, Cell and Tissue Research.

[27]  Barmak Modrek,et al.  T-helper type 2-driven inflammation defines major subphenotypes of asthma. , 2009, American journal of respiratory and critical care medicine.

[28]  Ana Sousa,et al.  Mepolizumab and exacerbations of refractory eosinophilic asthma. , 2009, The New England journal of medicine.

[29]  J. Hankinson,et al.  Standardisation of spirometry , 2005, European Respiratory Journal.

[30]  G H Guyatt,et al.  Development and validation of a questionnaire to measure asthma control. , 1999, The European respiratory journal.

[31]  G. Guyatt,et al.  Development and validation of the Mini Asthma Quality of Life Questionnaire. , 1999, The European respiratory journal.

[32]  I. Pavord,et al.  Non-eosinophilic cor ticosteroid unresponsive asthma , 1999, The Lancet.

[33]  P. Jones,et al.  The St George's Respiratory Questionnaire. , 1991, Respiratory medicine.